Every 8-K that IDEAYA Biosciences, Inc. (IDYA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IDYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDYA filings page.
IDEAYA Biosciences reported second-quarter 2026 collaboration revenue of $8.9 million and a net loss of $112.5 million, driven mainly by $108.7 million in research and development spending and $22.5 million in general and administrative expenses. Cash, cash equivalents and marketable securities were approximately $1.24 billion as of June 30, 2026, and management reiterated cash runway guidance into 2030.
The registrational Phase 2/3 -02 darovasertib plus crizotinib trial in HLA*A2:01-negative metastatic uveal melanoma met its primary endpoint, showing median progression-free survival of 6.9 months versus 3.1 months for investigator’s choice by blinded independent central review. A new drug application is underway under the FDA’s real-time oncology review program, alongside broad pipeline progress in ADC, MTAP-pathway, and KAT6/7 programs and a recent $323.4 million equity financing.
IDEAYA Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026. As of the April 20, 2026 record date, 87,860,920 common shares were outstanding and entitled to vote.
Stockholders voted on three proposals. For director elections, Yujiro S. Hata received 70,546,418 votes for and 2,470,077 withheld, M. Garret Hampton received 56,718,637 for and 16,297,858 withheld, and Catherine J. Mackey received 70,281,521 for and 2,734,974 withheld, with 10,089,343 broker non-votes for each nominee.
PricewaterhouseCoopers LLP, as independent registered public accounting firm for the year ending December 31, 2026, received 82,579,758 votes for, 141,240 against, and 384,840 abstentions. The non-binding advisory vote on executive compensation received 64,269,756 votes for, 8,349,131 against, 397,608 abstentions, and 10,089,343 broker non-votes.
Effective June 16, 2026, the Board elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as Lead Independent Director.
IDEAYA Biosciences, Inc. completed a sizable equity offering under an underwriting agreement with multiple investment banks. The company sold 7,222,225 shares of common stock, including full exercise of the underwriters’ 1,666,669-share option, and issued pre-funded warrants to purchase 5,555,576 additional shares. The public offering price was $27.00 per share and $26.9999 per pre-funded warrant, with the underwriters purchasing at discounted prices of $25.38 and $25.3799, respectively. IDEAYA reports net proceeds of approximately $323.6 million, after underwriting discounts and estimated expenses, providing substantial new capital for the business. Directors, executive officers and the company agreed to a 60-day lock-up on most share sales, and the securities were issued off an automatically effective shelf registration statement on Form S-3.
IDEAYA Biosciences reported a new clinical collaboration with Roche to study IDEAYA’s investigational PRMT5 inhibitor IDE892 with Roche’s pan-RAS inhibitor RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA will sponsor the trial and Roche will provide RG6505, with both companies retaining commercial rights to their respective drugs.
IDE892 is already in a Phase 1 dose-escalation trial in MTAP-deleted solid tumors, and IDEAYA plans Phase 1 combination cohorts in pancreatic cancer with RG6505 and in other tumors with its MAT2A inhibitor IDE397. The collaboration may also expand to a triplet regimen of IDE892, RG6505 and IDE397 under joint governance between the companies.
IDEAYA Biosciences reported complete primary analysis data from its global registrational Phase 2/3 -02 trial of darovasertib plus crizotinib as first-line therapy for HLA-A*02:01–negative metastatic uveal melanoma. In 313 randomized patients, the combination showed a median progression-free survival of 6.9 months versus 3.1 months for investigator’s choice therapy.
By blinded independent central review, the regimen reduced the risk of disease progression or death by 58% (hazard ratio 0.42) and achieved a 37.1% objective response rate compared with 5.8% for control. Disease control rate was 73.3% versus 31.1%. Safety findings were consistent with prior experience, with 9.2% treatment-related serious adverse events and low discontinuation rates.
The FDA has agreed to review IDEAYA’s new drug application for this combination under the Oncology Center of Excellence Real-Time Oncology Review program, and the company expects to complete the filing in the second half of 2026. Overall survival data are immature and will be presented later.
IDEAYA Biosciences, Inc. filed a new automatic shelf registration statement on Form S-3ASR and an at-the-market prospectus supplement that together cover potential common stock sales with aggregate gross proceeds of up to $156.6 million under its existing Open Market Sales Agreement with Jefferies LLC.
The new shelf replaces a prior automatic shelf that would have expired in June 2026, which is deemed terminated as of the new statement’s effective date. IDEAYA has previously sold common stock with an aggregate gross sales price of $193,447,003.19 under this agreement, and the remaining capacity is now available for discretionary future sales.
IDEAYA Biosciences reported a larger net loss for the first quarter of 2026 while highlighting major progress in its oncology pipeline. The company posted a net loss of $98.5 million, compared with $83.3 million in the prior quarter, on collaboration revenue of $6.6 million.
Cash, cash equivalents and marketable securities totaled $972.9 million as of March 31, 2026, and IDEAYA reiterated cash runway guidance into 2030. Research and development expenses rose to $95.7 million, reflecting increased clinical activity, while general and administrative costs were $19.4 million.
The company reported that its Phase 2/3 registrational trial of darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma met its primary endpoint, reducing the risk of disease progression by 58% with median progression-free survival of 6.9 months versus 3.1 months for investigator choice of therapy. IDEAYA plans a new drug application in the second half of 2026 under the FDA’s Real-Time Oncology Review program and outlined multiple additional clinical milestones across its ADC and synthetic lethality portfolio through 2026 and 2027.
IDEAYA Biosciences reported strong positive Phase 2/3 data for darovasertib plus crizotinib in first-line metastatic uveal melanoma. In 313 patients, the combination cut the risk of disease progression by 58% versus investigator’s choice therapy, with a hazard ratio of 0.42 and p<0.0001.
Median progression-free survival was 6.9 months on the combination versus 3.1 months on standard regimens, and overall response rate was 37.1% versus 5.8%. Five complete responses were seen on the combination and none in the control arm. Safety was generally manageable, and IDEAYA plans to submit a U.S. NDA in the second half of 2026.
IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDEAYA’s investigational DLL3 TOP1 antibody-drug conjugate IDE849 together with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer.
IDEAYA will sponsor the combination study, while AstraZeneca supplies Imfinzi. IDEAYA is running a multi-site global Phase 1 clinical trial of IDE849 in DLL3 upregulated solid tumors, including small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma, reflecting significant unmet medical need and the potential of DLL3 as a targeted therapy approach.
IDEAYA Biosciences reported fourth-quarter and full-year 2025 results alongside a major pipeline update. Collaboration revenue reached $10.9 million for the quarter and $218.7 million for 2025, driven by its darovasertib license with Servier. Cash, cash equivalents and marketable securities were about $1.05 billion as of December 31, 2025, and are expected to fund operations into 2030.
R&D expenses were $86.6 million in the quarter and $314.7 million for the year, while net loss narrowed to $83.3 million for the quarter and $113.7 million for the year, both improving versus 2024. The company highlighted progress for darovasertib in uveal melanoma, with required progression-free-survival events reached in its Phase 2/3 trial and topline data expected around the last week of March, and plans for three Phase 3 registrational trials by the first half of 2026.
IDEAYA also advanced additional programs, including IDE849 and IDE034 in antibody-drug conjugates, IDE161, IDE397 and IDE892 in MTAP-pathway targeting, and IDE574 in next-generation therapies, while preparing for commercial readiness and assuming full control of certain programs as GSK exits a prior collaboration.
IDEAYA Biosciences filed an 8-K describing a business update and outlining key corporate objectives for 2026 that it plans to present at the 44th Annual J.P. Morgan Healthcare Conference. The company highlights plans to advance four registrational trials, including IDE849, a Phase 1 DLL3 TOP1 antibody‑drug conjugate being developed as a monotherapy in neuroendocrine cancer, and darovasertib in both pre‑metastatic and metastatic uveal melanoma. The objectives span several focus areas such as darovasertib in uveal melanoma, ADC and DNA damage response combinations, the MTAP pathway, and next‑generation therapies, along with broader corporate goals. The filing also reiterates that these plans and anticipated timelines are forward‑looking and subject to clinical, regulatory, and operational risks.
IDEAYA Biosciences, Inc. filed a current report to note that it has posted an updated corporate presentation to the investor section of its website and furnished the same presentation as Exhibit 99.1. The presentation is dated January 12, 2026 and is intended to provide summary information about the company.
The company states that this information is being furnished under a disclosure item for investor presentations, not filed, so it is not subject to certain liability provisions of the securities laws and will not be automatically incorporated into other SEC filings. The presentation includes a Safe Harbor Statement addressing forward-looking statements.
IDEAYA Biosciences reports that GlaxoSmithKline Intellectual Property (No. 4) Limited has elected to terminate their Collaboration, Option and License Agreement dated June 15, 2020. The termination becomes effective on March 9, 2026, ninety days after GSK’s written notice on December 9, 2025.
During this 90-day transition period, GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs back to IDEAYA. The company plans to evaluate strategic options for these two programs in 2026 and states that this update does not change its expectation of a cash runway into 2030.
IDEAYA also includes forward-looking statements highlighting risks typical for drug development, such as early-stage program uncertainty, clinical and regulatory processes, manufacturing and commercialization challenges, pricing and reimbursement negotiations, protection of intellectual property, and factors that could affect whether existing cash is sufficient to fund operations.
IDEAYA Biosciences, Inc. furnished a current report describing that it announced its financial results for the third quarter ended September 30, 2025. The company did this through a press release dated November 4, 2025, which is included as Exhibit 99.1.
The report clarifies that the earnings information and the press release are being furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
IDEAYA Biosciences (IDYA) reported new Phase 2 clinical outcomes for its darovasertib plus crizotinib combination in first-line metastatic uveal melanoma. In 44 patients with a median follow-up of 25 months (cut-off May 28, 2025), the trial observed a median overall survival of 21.1 months and median progression-free survival of 7.0 months. Among 41 efficacy-evaluable patients, the confirmed overall response rate was 34% (14/41) with a 9.0‑month median duration of response, and disease control reached 90% (37/41). Historical median overall survival in treatment‑naïve mUM is approximately 12 months.
The regimen showed manageable tolerability; the most common treatment‑related adverse events (>30%) were diarrhea, nausea, edema, vomiting, dermatitis, hypoalbuminemia and fatigue, with grade ≥3 events of iron‑deficiency anemia and pulmonary embolism (both 5%). IDEAYA is running a registration‑enabling Phase 2/3 trial (OptimUM‑02) targeting median PFS readout by year‑end 2025 to Q1 2026, and a Phase 3 neoadjuvant trial (OptimUM‑10) in primary uveal melanoma. Pfizer is supplying defined quantities of crizotinib under a collaboration and supply agreement.
IDEAYA Biosciences filed an Form 8-K reporting material event updates tied to its OptimUM-10 trial of darovasertib. The company states that all efficacy-evaluable patients had received three or more cycles of treatment and had both baseline and on-treatment tumor assessments, paired dosimetry, and visual acuity score data available as of the stated cut-off. A median or representative follow-up duration of 3.5 months is reported for post-baseline scans, and the filing notes the study has not yet achieved a fully mature confirmed overall response rate (ORR%). The 8-K references the company’s 10-K and other SEC reports and is signed by Yujiro Hata, President and CEO.
IDEAYA Biosciences, Inc. disclosed that an upfront payment together with expected cost savings from an agreement are expected to extend the company’s cash runway by at least twelve months and, based on the company’s current operating plan, fund planned operations into 2030. The filing references mid-teens to low-twenties percentages in the text but does not provide further detail on what those percentages measure. The company also notes its 10-K was filed with the SEC on February 18, 2025. The report is signed by Yujiro Hata, President and Chief Executive Officer, dated September 2, 2025.
IDEAYA Biosciences (Nasdaq: IDYA) filed an 8-K disclosing a material C-suite change. On June 26 2025, the Board appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer under Item 5.02. The filing states the appointment is effective immediately and made pursuant to Section 16(a)-1(f) of the Exchange Act.
No resignations, compensation terms, financial guidance or other business updates were provided. Investors should monitor upcoming filings for any strategic or financial initiatives led by the new CFO.
IDEAYA Biosciences held its 2025 Annual Meeting of Stockholders on June 24, 2025, where shareholders voted on three key proposals:
- Director Elections: Jeffrey L. Stein, Ph.D. was elected with strong support (69,077,770 votes for), while Scott W. Morrison received more divided support (42,132,938 votes for, 34,900,780 withheld)
- Auditor Ratification: PricewaterhouseCoopers LLP was approved as the independent auditor for FY2025 with overwhelming support (79,645,454 votes for)
- Executive Compensation: The non-binding advisory vote on executive compensation passed but showed significant dissent (59,798,805 for vs 17,040,207 against)
Out of 87,577,550 total outstanding shares eligible to vote, the meeting saw substantial shareholder participation. The split vote on Morrison's directorship and significant opposition to executive compensation suggests some shareholder concerns about governance and compensation practices.